Previous 10 | Next 10 |
EnACT study of MAT2203 in cryptococcal meningitis received unanimous D ata and Safety Monitoring Board (DSMB) recommendation to pro ceed into second patient cohort – ENHANCE-IT s tudy of MAT9001 against Vascepa ...
Matinas Biopharma (MTNB): Q3 GAAP EPS of -$0.03 in-line.Revenue of $0.09M beats by $0.07M.Shares +4.09% PM.Press Release For further details see: Matinas Biopharma EPS in-line, beats on revenue
BEDMINSTER, N.J., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Friday, November 6, 2020 at 8:30 a.m. ET to discuss ...
Matinas BioPharma reports progress for EnACT study of MAT2203. iCAD announces positive data for Xoft in recurrent glioblastoma. AbbVie receives full FDA approval for Venclexta. For further details see: Matinas Reports Trial Progress, And Other News: The Good, Bad And Ugl...
– DSMB evaluated both safety and efficacy data in recommending cohort progression – – Enrollment in s econd cohort of patients expected to commence imminently with next DSMB evaluation anticipated mid- 2021 ...
- FDA Agreement to Move Directly into Phase 3 - - FDA to Require a Single Phase 3 Trial of 12 Weeks Duration to Support Efficacy for an NDA filing in SHTG - BEDMINSTER, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-sta...
BEDMINSTER, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced the appointment of Natasha Giordano to its Board of Directors as an independent director and a member of the audit committee, effective Monday, September 14, 2020. ...
BEDMINSTER, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate on a panel of top innovators in anti-infective drug development as part of Maxim Grou...
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...
BeiGene signs deal with Singlomics for neutralizing COVID-19 antibodies BeiGene Ltd. ( BGNE ) announced that it has inked a new deal with Singlomics Biopharmaceuticals Co. for developing, manufacturing and commercializing various anti-COVID-19 antibodies, including DXP-593 and DXP-604. U...
News, Short Squeeze, Breakout and More Instantly...
Matinas Biopharma Holdings Inc. Company Name:
MTNB Stock Symbol:
NYSE Market:
Matinas Biopharma Holdings Inc. Website:
BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful...
BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its ora...
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data ...